Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna, Inc. (NASDAQ: MRNA) is a cutting-edge biotech company based in Cambridge, Massachusetts, founded in 2010. Moderna is at the forefront of pioneering messenger RNA therapeutics™, a revolutionary class of drugs that utilize mRNA technology to direct cells to produce proteins that can fight diseases. This innovative approach has shown promise in addressing targets that were previously considered untreatable with traditional drugs.
With over 200 patent applications and more than 10,000 claims, Moderna has a robust intellectual property portfolio that includes novel nucleotide chemistries and specific drug compositions. The company has successfully developed and commercialized several mRNA-based drugs, initially focusing on rare diseases and oncology, while partnering to advance drug candidates in other therapeutic areas.
Moderna’s mRNA technology gained global recognition with its COVID-19 vaccine, Spikevax®, which was one of the earliest vaccines to receive emergency use authorization in the United States in December 2020. As of mid-2023, Moderna had 39 mRNA development candidates in clinical trials, covering a wide range of therapeutic areas such as infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders.
Some of Moderna's recent achievements include the advancement of three new vaccine programs—targeting Epstein-Barr virus, Varicella-Zoster virus, and norovirus—towards Phase 3 clinical trials. Additionally, the company initiated three new clinical studies combining its investigational individualized neoantigen therapy with Merck’s Keytruda® for treating various cancers.
Financially, Moderna reported first-quarter revenues of $167 million in 2024, with a GAAP net loss of $1.2 billion. Despite the decline in COVID-19 vaccine sales, the company reaffirms its 2024 expected product sales of approximately $4 billion. Moderna is preparing for the launches of its RSV vaccine and the Spikevax® 2024-2025 formula, demonstrating its commitment to fighting respiratory illnesses.
Moderna continues to focus on innovation and operational efficiency, utilizing AI technologies to enhance productivity. The company's long-term vision includes leveraging its mRNA platform to develop therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases, striving to make a significant impact on global health.
Moderna is set to collaborate with the Australian Government to establish a state-of-the-art mRNA vaccine manufacturing facility in Victoria, Australia. This facility is expected to produce up to 100 million vaccine doses annually, providing local access to vaccines against respiratory viruses. The agreement aims to enhance Australia's pandemic response capabilities and ensure quick access to Moderna's vaccines. The collaboration underscores a commitment to global public health and sustainable business practices amidst ongoing public health challenges.
Moderna (NASDAQ: MRNA) has announced an amendment to its contract with Gavi to accelerate supply, providing a total of 54 million doses to COVAX in 2021. An additional agreement allows for 20 million doses in Q2 2022, raising the total to 136.5 million doses. Gavi retains options to procure up to 650 million doses through 2022. Deliveries to COVAX AMC countries have commenced, highlighting Moderna's commitment to vaccine accessibility globally.
Moderna announced positive interim results from its Phase 1 study of the quadrivalent flu vaccine candidate, mRNA-1010, showing robust immune responses across all tested doses in both younger and older adults. The Phase 2 study has been fully enrolled, with preparations for a Phase 3 study already in progress. Moderna also introduced two new vaccine candidates, mRNA-1011 and mRNA-1012, aimed at expanding strain coverage. The company is focused on developing a pan-respiratory annual booster vaccine to combat significant health threats posed by respiratory infections.
Moderna, Inc. (Nasdaq: MRNA) announced it will host a live conference call on the Phase 1 interim analysis of its seasonal influenza vaccine candidate, mRNA-1010, on December 10, 2021, at 8:00 a.m. ET. Investors can access the call by dialing 866-922-5184 (domestic) or 409-937-8950 (international), referencing conference ID 8748887. A webcast will also be available on the Moderna website. Since its inception, Moderna has transformed into a leader in mRNA therapeutics, with a diverse clinical portfolio and significant manufacturing capabilities.
Moderna has launched an Artificial Intelligence Academy in collaboration with Carnegie Mellon University, aiming to enhance employee skills in AI and machine learning. This initiative will facilitate immersive learning experiences for Moderna employees at all levels, enabling them to incorporate AI solutions into the company's processes. The program will commence with its first cohort next week, targeting a broader rollout in early 2022. Moderna believes this investment is crucial for expanding mRNA technologies in the coming years.
Moderna (NASDAQ: MRNA) has announced a revised supply agreement with the UK government for up to 60 million doses of its COVID-19 vaccine. The delivery schedule includes 29 million doses in 2022 and 31 million in 2023, with a provision for the UK to increase or decrease orders by 20%. CEO Stéphane Bancel expressed gratitude for the UK government's support, emphasizing ongoing efforts to combat the pandemic. The agreement underscores Moderna's rapid scaling capabilities and its collaborative approach to vaccine distribution.
Moderna (NASDAQ: MRNA) announced updates to its strategy in response to the Omicron variant of SARS-CoV-2. The company is testing three existing COVID-19 vaccine booster candidates, including mRNA-1273 and higher doses (100 µg). Moderna is also developing two multi-valent booster candidates, mRNA-1273.211 and mRNA-1273.213, targeting mutations in the Omicron variant. Additionally, they are advancing an Omicron-specific candidate (mRNA-1273.529). These efforts aim to counteract waning immunity and address concerns regarding the variant's transmissibility and potential immune escape.
Moderna (NASDAQ: MRNA), a leader in messenger RNA therapeutics, has announced its participation in two upcoming virtual investor conferences on December 1. The NASDAQ 45th Investor Conference will take place at 9:30 a.m. ET, followed by the Piper Sandler 33rd Annual Virtual Healthcare Conference at 2:00 p.m. ET. Investors can access live webcasts of both presentations on Moderna's website, where replays will also be available for 30 days. Moderna has significantly advanced in mRNA science, especially in developing COVID-19 vaccines.
Moderna, Inc. (NASDAQ: MRNA) announced that the CDC's Advisory Committee on Immunization Practices (ACIP) has unanimously recommended the use of a booster dose of its COVID-19 vaccine for individuals aged 18 and older, following FDA's Emergency Use Authorization.
This recommendation aims to enhance protection against COVID-19 during the winter months as cases rise. Moderna's CEO, Stéphane Bancel, emphasized the importance of this step in combating the pandemic with their mRNA vaccine.
Moderna (MRNA) announced the FDA has extended emergency use authorization for its COVID-19 vaccine booster at a 50 µg dose for all adults aged 18 and older. This decision allows the booster to be administered to individuals who completed primary vaccination with any approved COVID-19 vaccine. The authorization is seen as critical due to rising COVID-19 cases. The FDA's decision was based on data from a Phase 2 study indicating a significant immune response from the booster dose. The CDC will meet to discuss rollout recommendations.
FAQ
What is the current stock price of Moderna (MRNA)?
What is the market cap of Moderna (MRNA)?
What is Moderna’s core business?
What are some recent achievements of Moderna?
How did Moderna gain global recognition?
What is Moderna’s financial outlook for 2024?
What is the significance of Moderna’s mRNA technology?
Where is Moderna headquartered?
How many mRNA development candidates does Moderna have?
What areas does Moderna’s mRNA platform cover?
How is Moderna enhancing its operations?
What is Moderna’s approach to partnerships?
